Phase 3CompletedAge-related condition

A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis

Sponsor
UCB Biopharma SRL (Industry)
Enrollment
327 enrolled
Conditions
Osteoporosis
Interventions
Romosozumab; Placebo
Ages
adults, older adults
Registry
NCT05067335

Full record on ClinicalTrials.gov

From the registry

The purpose of the study is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on the percent changes in bone mineral density (BMD) at the lumbar spine, at the total hip and femoral neck in postmenopausal Chinese women with osteoporosis.

Primary outcomes

  • Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine to the End of Double-Blind Period
  • Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period
  • Percentage of Participants With Treatment-emergent Adverse Events for Romosozumab During Overall Period

History

  1. Last registry update

  2. Results first posted

  3. Primary completion

  4. Started

  5. Registered